Joint effect of myocardial infarction and obesity on the risk of venous thromboembolism: The Tromsø Study.
epidemiology
myocardial infarction
obesity
risk factor
venous thromboembolism
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
08
06
2022
received:
07
03
2022
accepted:
07
07
2022
pubmed:
12
7
2022
medline:
23
9
2022
entrez:
11
7
2022
Statut:
ppublish
Résumé
Myocardial infarction (MI) is associated with an increased risk of venous thromboembolism (VTE). Obesity is a recognized risk factor for both MI and VTE. Whether obesity further increases the risk of VTE in MI patients is scarcely investigated. To study the joint effect of MI and obesity on the risk of VTE. Study participants (n = 29 410) were recruited from three surveys of the Tromsø Study (conducted in 1994-1995, 2001, and 2007-2008) and followed up through 2014. All incident MI and VTE cases during follow-up were recorded. Cox regression models with MI as a time-dependent variable were used to estimate hazard ratios (HRs) of VTE (adjusted for age and sex) by combinations of MI exposure and obesity status. Joint effects were assessed by calculating relative excess risk and attributable proportion (AP) due to interaction. During a median of 19.6 years of follow-up, 2090 study participants experienced an MI and 784 experienced a VTE. Among those with MI, 55 developed a subsequent VTE, yielding an overall incidence rate (IR) of VTE of 5.3 per 1000 person-years (95% confidence interval [CI]: 4.1-6.9). In the combined exposure group (MI+/Obesity+), the IR was 11.3 per 1000 person-years, and the adjusted HR indicated a 3-fold increased risk of VTE (HR 3.16, 95% CI: 1.99-4.99) compared to the reference group (MI-/Obesity-). The corresponding AP was 0.46 (95% CI: 0.17-0.74). The combination of MI and obesity yielded a supra-additive effect on VTE risk of which 46% of the VTE events were attributed to the interaction.
Sections du résumé
BACKGROUND
Myocardial infarction (MI) is associated with an increased risk of venous thromboembolism (VTE). Obesity is a recognized risk factor for both MI and VTE. Whether obesity further increases the risk of VTE in MI patients is scarcely investigated.
AIM
To study the joint effect of MI and obesity on the risk of VTE.
METHODS
Study participants (n = 29 410) were recruited from three surveys of the Tromsø Study (conducted in 1994-1995, 2001, and 2007-2008) and followed up through 2014. All incident MI and VTE cases during follow-up were recorded. Cox regression models with MI as a time-dependent variable were used to estimate hazard ratios (HRs) of VTE (adjusted for age and sex) by combinations of MI exposure and obesity status. Joint effects were assessed by calculating relative excess risk and attributable proportion (AP) due to interaction.
RESULTS
During a median of 19.6 years of follow-up, 2090 study participants experienced an MI and 784 experienced a VTE. Among those with MI, 55 developed a subsequent VTE, yielding an overall incidence rate (IR) of VTE of 5.3 per 1000 person-years (95% confidence interval [CI]: 4.1-6.9). In the combined exposure group (MI+/Obesity+), the IR was 11.3 per 1000 person-years, and the adjusted HR indicated a 3-fold increased risk of VTE (HR 3.16, 95% CI: 1.99-4.99) compared to the reference group (MI-/Obesity-). The corresponding AP was 0.46 (95% CI: 0.17-0.74).
CONCLUSIONS
The combination of MI and obesity yielded a supra-additive effect on VTE risk of which 46% of the VTE events were attributed to the interaction.
Identifiants
pubmed: 35815348
doi: 10.1111/jth.15812
pmc: PMC9796784
pii: S1538-7836(22)19046-X
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2342-2349Informations de copyright
© 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.
Références
Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):226-30
pubmed: 24177328
Semin Thromb Hemost. 2013 Jul;39(5):533-40
pubmed: 23625755
Br J Haematol. 2007 Oct;139(2):289-96
pubmed: 17897305
J Thromb Haemost. 2016 Jun;14(6):1183-91
pubmed: 27061154
J Thromb Haemost. 2022 Oct;20(10):2342-2349
pubmed: 35815348
Nat Rev Cardiol. 2021 Sep;18(9):666-682
pubmed: 33958774
Br J Haematol. 2011 Aug;154(4):486-91
pubmed: 21671893
Eur J Intern Med. 2009 Sep;20(5):470-3
pubmed: 19712846
PLoS One. 2016 Sep 16;11(9):e0163242
pubmed: 27635655
J Clin Epidemiol. 1988;41(2):105-14
pubmed: 3335877
J Intern Med. 2015 May;277(5):573-84
pubmed: 25161014
Thromb Haemost. 2019 Aug;119(8):1358-1364
pubmed: 31203579
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
J Thromb Haemost. 2009 Apr;7(4):521-8
pubmed: 19192118
Circulation. 2011 Sep 27;124(13):1435-41
pubmed: 21900083
Am J Epidemiol. 2010 May 15;171(10):1109-15
pubmed: 20418276
Pharmacol Ther. 2018 Jun;186:73-87
pubmed: 29330085
Annu Rev Immunol. 2011;29:415-45
pubmed: 21219177
Lancet. 1999 Apr 3;353(9159):1167-73
pubmed: 10209995
Hum Genet. 2017 Jul;136(7):897-902
pubmed: 28528403
Thromb Haemost. 2017 Jan 26;117(2):390-400
pubmed: 27975103
Circulation. 1994 Jul;90(1):61-8
pubmed: 8026047
J Thromb Haemost. 2017 Dec;15(12):2344-2351
pubmed: 28981216
Arterioscler Thromb Vasc Biol. 2011 Jun;31(6):1439-44
pubmed: 21527750
Circulation. 2017 Jan 3;135(1):7-16
pubmed: 27831499
Eur J Epidemiol. 2011 Jun;26(6):433-8
pubmed: 21344323
J Thromb Haemost. 2016 Aug;14(8):1561-71
pubmed: 27208592
Eur J Epidemiol. 2005;20(7):575-9
pubmed: 16119429
Int J Epidemiol. 2012 Aug;41(4):961-7
pubmed: 21422063
J Am Coll Cardiol. 2020 Jan 21;75(2):148-158
pubmed: 31948643
Chest. 2012 Feb;141(2 Suppl):7S-47S
pubmed: 22315257
ESC Heart Fail. 2021 Feb;8(1):222-237
pubmed: 33319509
Eur J Epidemiol. 2014 Nov;29(11):821-30
pubmed: 25213403